savella new drug fda approved for fibromyalgia

Discussion in 'Fibromyalgia Main Forum' started by hensue, Jan 15, 2009.

  1. hensue

    hensue New Member

    has anyone tried this drug? or been in the trial? Would like to know i take wellbutrin.
    I do have high blood pressure but under control. Does anyone know about it or someone who has tried it?
    Thanks
    Hensue
  2. cj368

    cj368 New Member

    I have been part of the drug study for two years. This drug has changed my life. I am virtually pain free with almost no side-effects. I have some bad days...especially when my stress level is high or I do too much. But those bad days are few and most days I function really well. I believe it's worth a conversation with your doctor. Good luck.
  3. can anyone tell me what type of drug is this and what is it supposed to do? Can we get it NOW? maybe this was one of the new meds my dr. mentioned was coming out soon.
  4. hensue

    hensue New Member

    How long and what side affects have you had if any? That is very encouraging! Sounds really great and i am excited. Please tell us more!
    Thanks a bunch
    Hensue
  5. cj358 or anyone who has used it. I also wondered if you tried lyrica /cymbalta or neurontin before this or what did you try. How fast did you notice relief, what dosage do you take?
  6. just found this here in the library

    Savella, just approved on January 14, 2009, will not be widely available in US pharmacies until March.
  7. charlenef

    charlenef New Member

    Fatigue in Fibromyalgia Syndrome Patients
    December 13, 2002

    Cypress Bioscience Inc.'s Milnacipran Significantly Improves Pain and Fatigue in Fibromyalgia Syndrome Patients.

    Milnacipran, Cypress Bioscience Inc.'s (NASDAQ:CYPB) drug currently being evaluated for treatment of the Fibromyalgia Syndrome (FMS) was shown to provide statistically significant improvement of pain and fatigue symptoms in a preliminary analysis of the Company's Phase II clinical trial.

    This trial is the first to evaluate milnacipran as a potential treatment for FMS.

    FMS is a chronic pain syndrome that is estimated to affect 2-4% of the general population. The symptoms of FMS can be debilitating, and are characterized by chronic and widespread pain throughout the body, often accompanied by severe fatigue and poor sleep. Treatment options are limited as there are no drugs specifically approved by the U.S. Food and Drug Administration for the treatment of FMS.

    A preliminary analysis of the randomized, double blind, placebo-controlled, flexible dose escalation mono-therapy trial was conducted on 95 patients, or 76% of the total patients enrolled in the trial, who had completed the trial as of Oct. 31, 2002. A total of 125 patients are enrolled in the trial - the remaining 30 patients have recently completed the study. Patients were randomized to receive placebo or milnacipran (either once or twice per day) for four weeks of dose escalation, followed by eight weeks of constant dose.

    The study evaluated the efficacy and safety of milnacipran for the treatment of pain and associated symptoms such as fatigue, depressed mood and sleep. Patients were asked to characterize their pain, fatigue, sleep and related symptoms several times each day on an electronic diary.


    Milnacipran-treated patients randomized to the twice a day dosing group (BID) showed statistically significant improvements in pain compared to those who received placebo. Of the 95 patients that had completed the trial as of the date of this analysis, 87 percent of all milnacipran-treated patients reported overall improvement, compared to 33 percent in the placebo group (p less than 0.001). Further, 36 percent of milnacipran BID-treated patients reported at least a 50 percent reduction in pain intensity, compared to 9 percent of patients who received placebo, a difference that was statistically significant (p=0.030, intent to treat analysis). In addition, milnacipran-treated patients showed significant improvements in fatigue and depressed mood.


    "It is extraordinary to see such a significant improvement in symptoms in this patient population," said Dr. Daniel Clauw, Professor of Medicine, Division of Rheumatology; director, Center for Advancement of Clinical Research; and director, Chronic Pain and Fatigue Research Center, The University of Michigan and chairman of Cypress' Rheumatology Advisory Board.

    "Attempts to treat the complex pain of FMS with existing medications have met with limited success," noted Jay D. Kranzler, MD, PhD, chairman of the board and chief executive officer of Cypress Bioscience Inc. "Milnacipran, a novel dual-acting reuptake inhibitor that acts on two key neurotransmitters in the human body, norepinephrine and serotonin, which are involved with the central modulation and processing of chronic pain, is distinguished from other dual reuptake inhibitors by its preference for norepinephrine reuptake inhibition over serotonin reuptake inhibition. Based on these preliminary results, milnacipran appears to have the potential to relieve several of the symptoms associated with FMS, and perhaps other related Functional Somatic Syndromes."

    Eighty-four percent of all milnacipran patients escalated to the highest dose with no tolerability issues. The most common dose-related side effect reported by patients was nausea, particularly early in the study. Most adverse events were mild to moderate in intensity, and transient in duration.

    A final analysis of the trial, including all enrolled patients, will be available early in 2003. It should be noted that response rates and significance levels may change when the final analysis is performed.

    About Cypress Bioscience Inc.

    Cypress is committed to be the innovator and commercial leader in providing products for the diagnosis and treatment of patients with Functional Somatic Syndromes, such as Fibromyalgia Syndrome, or FMS, and other related chronic pain and central nervous system disorders. In August 2001, Cypress licensed from Pierre Fabre Medicament its first product for clinical development, milnacipran. Milnacipran, the first of a new class of agents known as NSRI's, or Norepinephrine Serotonin Reuptake Inhibitors, shares a pharmacological profile with the tricyclic antidepressants (TCAs), considered the most effective drugs for treatment of FMS, while appearing to lack the side effects associated with the latter. Cypress recently completed a Phase II trial in which milnacipran is being evaluated as a potential treatment for FMS. For more information about Cypress, please visit the company's Web site at. For more information about FMS, please visit www.FMSresource.com.

    This press release, as well as Cypress' SEC filings and Web site at http://www.cypressbio.com, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including statements about the potential of milnacipran to treat FMS. Actual results could vary materially from those described as a result of a number of factors, including those set forth in Cypress Annual Report on Form 10-K and any subsequent SEC filings. In addition, there is the risk that the final results from the Phase II trail of milnacipran will be significantly different than the preliminary analysis, that we may not be able to successfully develop or market milnacipran or any other products for the treatment of FMS; that our clinical development plan or timeline for milnacipran may be delayed, including the final results of our Phase II clinical trial; that our current working capital will not allow us to execute our business plans into 2003; that we may encounter regulatory or other difficulties in the development of milnacipran for FMS; and that milnacipran may not significantly improve the treatment of FMS. Cypress undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.


  8. charlenef

    charlenef New Member

  9. cj368

    cj368 New Member

    I started out in the milnacipran study about two years ago. I was given the drug/placebo for about 6 months. I had a doctor diary where I had to answer questions about my pain level four or five times a day.

    I clearly had the placebo because I didn't have any change in my pain level. I had some good days that I hoped was the drug, however, it didn't last any length of time. I will never know officially if I had the placebo though.

    After my 6 month blind study I was given the drug starting at 25 mg. That level was increased by 25 mg every two weeks (I think). I started to feel a difference when I got up to about 100 mg. I have been at 150 mg for about 4 months now.

    My pain is so much better, my sleep has improved dramatically, and I have much less fibro fog.

    I have to keep my stress level down, I need to get activity in, and I have to be very careful about not over doing it. That's been the most difficult part because I feel so good. I had a few days this Christmas where I was reminded of how things used to be. I did way too much and suffered for a couple of days.

    Side effects...I really don't have many, none that I would trade the drug for. I have to eat before I take the meds because it does cause nausea. The most difficult one for me is loss of sex drive. However, I wasn't wanting much action before with all of the pain and exhaustion. I was able to lose 53 lbs while on the drug so it certainly doesn't cause weight gain like Lyrica, for me anyway.

    I am blessed to have been part of this study and I hope you all find relief soon.
  10. kat0465

    kat0465 New Member

    and almost any other drug when i read side effects, wish i could get over the phobia of that!! thin i'll wait a while before i ask to try it. still praying tho that this will be at least a light at the end of a very long tunnel!
  11. Jill

    Jill New Member

    HI! I am at the tail end of the study and it has done wonders for me. It literally helps me get through my day as a preschool teacher. What is great is that it is not a pain drug but it works! Try it --Jill
  12. catscats

    catscats New Member

    I recently got on the drug and it is causing me to have heart palpitations. Nothing to severe but enough to scare me a little! anyone else?
  13. MaxieJap

    MaxieJap New Member

    Sevilla is available, but please google it and read the entire insert. Lyrica almost ruined my life. I had every side effect, but none of my doctors realized it. They thought I had a brain tumor. I even broke a rib when I lost my balance which never really returned. My manual dexterity never returned to normal nor my fine motor skills. BTW, I'd be off any drug faster than a NY minute (safely) if it caused heart palpitations in me. I am currently on Cymbalta which was working but just stopped with extra stress in my life. This Sevilla drug sounds very scarey to me. Especially the liver damage part. I truly wonder how safe it is, especially if you are taking other meds for other probs, and your dr. doesn't recognize, as my rheumatologist didn't, that I am on a few no-nos which can kill you if you take this drug with them. Also, if you have a long history with your dr., he should be able to provide samples for you to help with the cost, if that is truly an issue. Any other info from those out there who have tried it?

    [This Message was Edited on 07/03/2009]
    [This Message was Edited on 07/03/2009]
    [This Message was Edited on 07/03/2009]